Generation of efficacy, toxicity and disease signatures and methods of use thereof

• US 20040121305A1
• Filed: 12/18/2002
• Published: 06/24/2004
• Est. Priority Date: 12/18/2002
• Status: Abandoned Application

• Current Assignee: Oxford Bioscience Partners IV LP (Oxford Bioscience Partners)
• Original Assignee: Oxford Bioscience Partners IV LP (Oxford Bioscience Partners)
• Inventors: Wei, Dong, Li, Lily Y. T., Crosas, Merce, Rogers, James Anthony, Wiegand, Roger Charles, Rosenberg, Alexander Frederic, McCarroll, Robert Michael
• Application Number:
  US10/323,493
• Publication Number:
  US 20040121305A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism

Abstract

The invention provides methods of generating small molecule efficacy profiles and signature, small molecule toxicity profiles and signatures and small molecule disease profiles and signatures. The invention also provides methods of determining the efficacy and/or toxicity of unknown agents and drugs in a subject and methods of diagnosing an unknown disease or disorder in a subject. The invention further provides methods of monitoring the progression or remission of a disease or disorder in a subject undergoing treatment and methods of measuring the effectiveness of treatment.

Claims

1. A method of generating a small molecule efficacy or toxicity profile for an agent, toxicant, or drug, wherein the profile is generated from a subject treated with said agent, toxicant, or drug, said method comprising the steps of:

a. isolating from said treated subject, a biological sample selected from the group consisting of organ, tissue, cell, cellular compartment, organelle, cerebrospinal fluid, synovial fluid, blood and urine;

b. extracting small molecules from said biological sample; and

c. analyzing said small molecules from said sample by mass spectroscopy,

wherein analyzing said small molecules results in the generation of a small molecule efficacy or toxicity profile.

2. The method of claim 1, wherein at least 170 specific small molecules are analyzed by mass spectroscopy.

3. The method of claim 2, wherein said mass spectroscopy analysis is capable of being performed in less than 10 minutes.

4. The method of claim 1, wherein mass spectroscopy analysis comprises staggering injections using a multiple column switching valve, wherein said valve allows combination of different column types into one injection.

5. The method of claim 1, wherein the concentration of each small molecule analyzed is below the concentration of 10 ng/ml.

6. The method of claim 1, which further comprises a computer system for tracking samples for small molecule profiling.

7. The method of claim 1, wherein said treated subject is human.

8. The method of claim 1, wherein said treated subject is a healthy reference subject.

9. The method of claim 1, wherein said treated subject suffers from a disease or disorder.

10. The method of claim 9, wherein said disease or disorder is selected from the group consisting of non-insulin-dependent diabetes (NIDDM), rheumatoid arthritis or inflammation (RA/I), immunological disorder, metabolic disorder, cardiovascular disorder, neurological disorder, oncological disorder, and viral disorder.

11. The method of claim 1, wherein said agent or drug is selected from the group consisting of Chlorpropamide, Tolbuamide, Tolazamide, Acetohexamide, Glyburide, Glipizide, Glimepiride, Pioglitazone, Rosiglitazone, Metformin, Acarbose (Precose), Miglitol (Glycet), Repaglinide (Prandin), Aspirin, Acetaminophen, Ibuprofen, Indomethacin, Peroxicam, Tometin, Rofecoxib, Celecoxib, Valdecoxib, Methotrexate, and Dexamethasone.

12. The method of claim 1, wherein said toxicant is selected from the group consisting of 2,2′

,4,4′

,5,5′

-hexachlorobiphenyl (PCB-

     153), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-bromoethylamine (BEA), 3-methylcholanthrene, 4-aminophenol (PAP), acetaminophen, adriamycin, allyl alcohol, amiodarone, amphotericin B, Aroclor 1254, Aroclor 1260, arsenic, aspirin, astemizole, benzene, cadmium, carbamezipine, carbon tetrachloride (CCl4), ciprofibrate (cipro), clofibrate, cobalt chloride, corvastatin, cyclosporin A, diethylntrosamine, dimethylformamide, dimethylhydrazine (DMH), diquat, ethosuximide, etoposide, famotidine, fluconazole, gamfibrozil, ganciclovir, hexachloro-1,3-butediene (HCBD), HIV protease inhibitors, hydrazine, indomethacin, interleukin-6 (IL-6), ketoconazole, lead acetate (PbAc), lipopolysaccharide (LPS), mercury(II) chloride (HgCl₂), methanol, methapyrilene, methotrexate, metronidazole, miconazole, monocrotaline, nitric oxide, ondansetron, pentamidine, phenobarbital, phenylhydrazine (phenylhyrzn), phenytoin, pravastatin, propulsid, puromycin aminonucleoside (PAN), quinolones, simvastatin, sodium fluoride (NaF), statins, thioacetamide, tocainidine, tricyclic antidepressants, troglitazone, tumor necrosis factor a (TNFα

), uranyl nitrate, valproic acid, vincristine, Wy-16,463, zidovudine (AZT), α

-naphthyl isothiocyanate (ANIT), and β

-naphthoflavone (BNF).

13. A method of generating a small molecule efficacy or toxicity signature for an agent, toxicant, or drug, said method comprising the steps of:

a. obtaining one or more small molecule efficacy or toxicity profiles from one or more treated subjects according to the method of claim 1;

b. obtaining one or more small molecule efficacy or toxicity profiles from one or more control subjects not treated with the agent, toxicant, or drug; and

c. comparing the one or more small molecule efficacy or toxicity profiles from one or more treated subjects to the one or more small molecule efficacy or toxicity profiles generated from the one or more untreated subjects,

wherein comparing said small molecule efficacy or toxicity profiles from the treated and untreated subjects results in the generation of a small molecule efficacy or toxicity signature for the agent, toxicant, or drug.

14. The method of claim 13, wherein said comparing comprises the steps of:

a. generating a data matrix, said matrix comprising two or more analyte/sample values indicating small molecule abundance in said sample;

b. log transforming said data matrix;

c. normalizing said transforming data matrix, said normalization comprising subtracting the median of all analyte/sample values from each analyte/sample value; and

d. performing variance analysis on said normalized data matrix,

thereby generating a small molecule efficacy or toxicity signature.

15. The method of claim 13, wherein said treated subject is human.

16. The method of claim 13, wherein said treated subject is a healthy subject.

17. The method of claim 13, wherein said treated subject suffers from a disease or disorder.

18. The method of claim 17, wherein said disease or disorder is selected from the group consisting of non-insulin-dependent diabetes (NIDDM), rheumatoid arthritis or inflammation (RA/I), immunological disorder, metabolic disorder, cardiovascular disorder, neurological disorder, oncological disorder, and viral disorder.

19. The method of claim 13, wherein said agent or drug is selected from the group consisting of Chlorpropamide, Tolbuamide, Tolazamide, Acetohexamide, Glyburide, Glipizide, Glimepiride, Pioglitazone, Rosiglitazone, Metformin, Acarbose (Precose), Miglitol (Glycet), Repaglinide (Prandin), Aspirin, Acetaminophen, Ibuprofen, Indomethacin, Peroxicam, Tometin, Rofecoxib, Celecoxib, Valdecoxib, Methotrexate, and Dexamethasone.

20. The method of claim 13, wherein said toxicant is selected from the group consisting of 2,2′

,4,4′

,5,5′

-hexachlorobiphenyl (PCB-153), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-bromoethylamine (BEA), 3-methylcholanthrene, 4-aminophenol (PAP), acetaminophen, adriamycin, allyl alcohol, amiodarone, amphotericin B, Aroclor 1254, Aroclor 1260, arsenic, aspirin, astemizole, benzene, cadmium, carbamezipine, carbon tetrachloride (CCl4), ciprofibrate (cipro), clofibrate, cobalt chloride, corvastatin, cyclosporin A, diethylntrosamine, dimethylformamide, dimethylhydrazine (DMH), diquat, ethosuximide, etoposide, famotidine, fluconazole, gamfibrozil, ganciclovir, hexachloro-1,3-butediene (HCBD), HIV protease inhibitors, hydrazine, indomethacin, interleukin-6 (IL-6), ketoconazole, lead acetate (PbAc), lipopolysaccharide (LPS), mercury(II) chloride (HgCl₂), methanol, methapyrilene, methotrexate, metronidazole, miconazole, monocrotaline, nitric oxide, ondansetron, pentamidine, phenobarbital, phenylhydrazine (phenylhyrzn), phenytoin, pravastatin, propulsid, puromycin aminonucleoside (PAN), quinolones, simvastatin, sodium fluoride (NaF), statins, thioacetamide, tocainidine, tricyclic antidepressants, troglitazone, tumor necrosis factor a (TNFα

), uranyl nitrate, valproic acid, vincristine, Wy-16,463, zidovudine (AZT), α

-naphthyl isothiocyanate (ANIT), and β

-naphthoflavone (BNF).

33. A method of predicting the efficacy of an agent or drug with an unknown efficacy, said method comprising the steps of:

a. generating a first small molecule efficacy signature of the agent or drug according to the method of claim 13;

b. obtaining one or more second small molecule efficacy signatures, wherein the one or more second small molecule efficacy signatures have been generated with agents or drugs with known efficacies;

comparing said first small molecule efficacy signature to the one or more second small molecule efficacy signatures, thereby predicting the efficacy of said agent or drug.

34. The method of claim 33, wherein the one or more second small molecule efficacy signatures are a database of small molecule efficacy signatures.

35. The method of claim 33, wherein the first and second small molecule efficacy signatures are similar, thereby predicting that the agent or drug with an unknown efficacy will have an efficacy similar to the agents or drugs with known efficacies used to generate the second small molecule efficacy profiles.

36. The method of claim 33, wherein the first and second small molecule efficacy signatures are different, thereby predicting that the agent or drug with an unknown efficacy will not have an efficacy similar to the agents or drugs with known efficacies used to generate the second small molecule efficacy profiles.

37. A method of determining the toxicity of an agent or drug with an unknown toxicity, said method comprising the steps of:

a. generating a first small molecule toxicity signature of the agent or drug according to the method of claim 13;

b. obtaining one or more second small molecule toxicity signatures, wherein the one or more second small molecule toxicity signatures have been generated with agents or drugs with known toxicities; and

c. comparing said first small molecule toxicity signature to the one or more second small molecule toxicity signatures,

thereby determining the toxicity of said agent or drug.

38. The method of claim 37, wherein the one or more second small molecule toxicity signatures are a database of small molecule toxicity signatures.

39. The method of claim 37, wherein the first and second small molecule toxicity signatures are similar, thereby determining that the agent or drug with an unknown toxicity will have a toxicity similar to the agents or drugs with known toxicities used to generate the second small molecule toxicity signatures.

40. The method of claim 37, wherein the first and second small molecule toxicity signatures are different, thereby predicting that the agent or drug with an unknown toxicity will not have a toxicity similar to the agents or drugs with known toxicities used to generate the second small molecule toxicity signatures.

21. A method of generating a small molecule disease profile from a subject suffering from a known or unknown disease or disorder, said method comprising the steps of:

a. isolating from said diseased subject, a biological sample selected from the group consisting of organ, tissue, cell, cellular compartment, organelle, cerebrospinal fluid, synovial fluid, blood and urine;

b. extracting small molecules from said biological sample; and

c. analyzing said small molecules from said sample by mass spectroscopy,

wherein analyzing said small molecules results in the generation of a small molecule disease profile.

22. The method of claim 21, wherein at least 170 specific small molecules are analyzed by mass spectroscopy.

23. The method of claim 22, wherein said mass spectroscopy analysis is capable of being performed in less than 10 minutes.

24. The method of claim 21, wherein mass spectroscopy analysis comprises staggering injections using a multiple column switching valve, wherein said valve allows combination of different column types into one injection.

25. The method of claim 21, wherein the concentration of each small molecule is below the concentration of 10 ng/ml.

26. The method of claim 21, which further comprises a computer system for tracking samples for small molecule profiling.

27. The method of claim 21, wherein said diseased subject is human.

28. The method of claim 27, wherein said disease or disorder is selected from the group consisting of non-insulin-dependent diabetes (NIDDM), rheumatoid arthritis or inflammation (RA/I), immunological disorder, metabolic disorder, cardiovascular disorder, neurological disorder, oncological disorder, and viral disorder.

29. A method of generating a small molecule disease signature for a disease or disorder, said method comprising the steps of:

a. obtaining one or more small molecule disease profiles for a subject suffering from a disease or disorder according to the method of claim 21;

b. obtaining one or more small molecule profiles from one or more non-diseased control subjects, wherein the control subjects do not suffer from the disease or disorder; and

c. comparing the one or more small molecule disease profiles from one or more diseased subjects to the one or more small molecule disease profiles generated from one or more non-diseased control subjects,

wherein comparing said small molecule disease profiles from the diseased subjects and non-diseased control subjects results in the generation of a small molecule disease signature for the disease or disorder.

30. The method of claim 29, wherein said comparing comprises the steps of:

a. generating a data matrix, said matrix comprising two or more analyte/sample values indicating small molecule abundance in said sample;

b. log transforming said data matrix;

c. normalizing said transforming data matrix, said normalization comprising subtracting the median of all analyte/sample values from each analyte/sample value; and

d. performing variance analysis on said normalized data matrix,

thereby generating a small molecule disease signature.

31. The method of claim 29, wherein said subject is human.

32. The method of claim 29, wherein said disease or disorder is selected from the group consisting of non-insulin-dependent diabetes (NIDDM), rheumatoid arthritis or inflammation (RA/I), immunological disorder, metabolic disorder, cardiovascular disorder, neurological disorder, oncological disorder, and viral disorder.

41. A method of diagnosing a disease or disorder in a subject with an unknown disease or disorder, said method comprising the steps of:

a. generating a small molecule disease profile of the subject according to the method of claim 21;

b. obtaining one or more small molecule disease signatures according to claim 29, wherein the one or more small molecule disease signatures have been generated from subjects with known diseases or disorders; and

c. comparing said small molecule disease profile to the one or more small molecule disease signatures,

thereby diagnosing the disease or disorder.

42. The method of claim 41, wherein the one or more small molecule disease signatures are a database of small molecule disease signatures.

43. The method of claim 41, wherein the small molecule disease profile of the subject and the small molecule disease signatures are similar, thereby diagnosing the subject with the disease or disorder of the subjects used to generate the small molecule disease signatures.

44. The method of claim 41, wherein the small molecule disease profile of the subject and the small molecule disease signatures are different, thereby diagnosing that the subject does not have the disease or disorder of the subjects used to generate the small molecule disease signatures.

45. A method of monitoring the progression or remission of a disease or disorder in a subject undergoing treatment for said disease or disorder, said method comprising the steps of:

a. obtaining a small molecule disease profile from said subject at the onset of treatment for said disease or disorder;

b. obtaining small molecule disease profiles from said subject at multiple times during the course of treatment for said disease or disorder; and

c. comparing the small molecule disease profiles from step b) with the small molecule disease profile obtained at the onset of treatment,

thereby measuring the effectiveness of said treatment and monitoring the progression or remission of said disease or disorder in said subject.